Combination of bevacizumab and lomustine with first recurrence of glioblastoma prolongs progression-free survival, but not overall survival

European Organisation for Research and Treatment of Cancer. "Combination of bevacizumab and lomustine with first recurrence of glioblastoma prolongs progression-free survival, but not overall survival." ScienceDaily. ScienceDaily, 23 November 2015. <http://ift.tt/1R1ho2t;.

European Organisation for Research and Treatment of Cancer. (2015, November 23). Combination of bevacizumab and lomustine with first recurrence of glioblastoma prolongs progression-free survival, but not overall survival. ScienceDaily. Retrieved November 23, 2015 from http://ift.tt/1jgk9iN

European Organisation for Research and Treatment of Cancer. "Combination of bevacizumab and lomustine with first recurrence of glioblastoma prolongs progression-free survival, but not overall survival." ScienceDaily. http://ift.tt/1jgk9iN (accessed November 23, 2015).